576 related articles for article (PubMed ID: 32020559)
21. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
22. Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS).
Araujo AGS; Borba HHL; Tonin FS; Lenzi L; Venson R; Pontarolo R; Wiens A
BioDrugs; 2018 Aug; 32(4):377-390. PubMed ID: 29873000
[TBL] [Abstract][Full Text] [Related]
23. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
24. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
25. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
[TBL] [Abstract][Full Text] [Related]
26. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
[TBL] [Abstract][Full Text] [Related]
27. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
28. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
29. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
Alvarez Y; Hidalgo A; Maignen F; Slattery J
Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
[TBL] [Abstract][Full Text] [Related]
30. Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration's Adverse Event Reporting System.
Pera V; van Vaerenbergh F; Kors JA; van Mulligen EM; Parry R; de Wilde M; Lahousse L; van der Lei J; Rijnbeek PR; Verhamme KMC
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5743. PubMed ID: 38158381
[TBL] [Abstract][Full Text] [Related]
31. Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems.
Gatti M; Fusaroli M; Raschi E; Capelli I; Poluzzi E; De Ponti F
J Nephrol; 2022 Apr; 35(3):1017-1027. PubMed ID: 34762277
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
33. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
34. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
35. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
36. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
37. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
38. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
[TBL] [Abstract][Full Text] [Related]
40. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]